JLR: Virtual issue sheds light on a key risk factor for heart disease
Because lipids such as cholesterol and triglycerides are hydrophobic and tend to clump up, rather than dissolve, in water, they need help getting around inside the body. Lipoproteins are complex assemblies with hydrophilic outer shells that package hydrophobic lipids in their core, allowing them to hitch a ride through the bloodstream. These delivery particles play an important role in the absorption of dietary lipids from the small intestine and also transport lipids to and from the liver.
The cover of the JLR virtual issue depicts the Lp(a) particle following the steps of a walking path, getting bigger as the road stretches into infinity.High levels of one particular class of lipoprotein, known as lipoprotein (a), are associated with atherosclerosis, inflammation and thrombosis, but no treatments are available in the clinic that specifically lower Lp(a), and much of what governs Lp(a) assembly is still unknown.
A new from the Journal of Lipid Research titled “Lipoprotein (a): Many strides made, yet there is a long road ahead” explores the past, present and future status of Lp(a) research and showcases researchers pushing this field forward. This issue was assembled by JLR Junior Associate Editor from Columbia University Irving Medical Center in New York City.
Several papers collected in this issue offer insights into how various Lp(a)-reducing drugs work. In one of these studies, and colleagues at the University of California, Davis, and the University of Hong Kong demonstrated that alirocumab — an inhibitor of the lipid-binding enzyme PCSK9 — could lower Lp(a) levels regardless of the isoform of proteins in Lp(a).
A study by and an international team of researchers suggests that another PCSK9 inhibitor, evolocumab, reduces Lp(a) levels partly by increasing the expression of LDL receptors.
Elisa Waldmann and at Ludwig Maximilian University of Munich wrote a review that discusses apheresis as an effective method of selectively clearing Lp(a) from the blood and reducing risk of cardiovascular disease.
Another review, penned by at McGill University, describes the association of Lp(a) with aortic valve disease and outlines steps toward developing much-needed preventive and therapeutic strategies.
Enjoy reading ASBMB Today?
Become a member to receive the print edition monthly and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Can a hair-loss drug prevent heart disease?
With the approved medication finasteride, researchers in Illinois may have found a new way to kill two birds with one stone.
These proteins have been secretly managing your cells
Scientists have long known that histones spool DNA and help regulate genes. They may be doing a lot more.
At the Salton Sea, uncovering the culprit of lung disease
Scientists have long suspected a link between the dust and poor respiratory health. According to recent findings, the prime suspect is a naturally occurring toxin.
From the journals: MCP
The importance of sharing proteomics data. Detecting nitrotyrosine-containing proteins. Analyzing yeast proteasomes. Read about these recent articles.
Using a network to snare the cause of kidney disease
A microfluidic device that mimics blood capillaries may help in early detection, and proper measures could reduce the risk of renal failures.
All about cholesterol
The latest science on how blood levels of HDL, LDL and more relate to cardiovascular health.